Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Company Successful with its Strategic Focus on Vaccines and Oncology Trials BERWYN, Pa., Sept. 9 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ:ENCO), a full-service multinational...
BERWYN, Pa., Aug. 31 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ:ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for...
WAYNE, Pa., Aug. 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ:ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for...
WAYNE, Pa., July 1 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and...
Net Loss Significantly Reduced to $195,220 in First Quarter on Cost Cutting WAYNE, Pa., May 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full service multinational...
WAYNE, Pa., May 18 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and...
WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and...
WAYNE, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for...
WAYNE, Pa., Oct. 1 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
